把这个新闻移除吧，这_老虎社区_美港股上老虎

2025-04-04

把这个新闻移除吧，这关键字抓取的[捂脸]

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":420518995935528,"tweetId":"420518995935528","gmtCreate":1743696874435,"gmtModify":1743696875907,"author":{"id":3472640255046348,"idStr":"3472640255046348","authorId":3472640255046348,"authorIdStr":"3472640255046348","name":"回心转意","avatar":"https://static.tigerbbs.com/53f698175ab5e3e0270c3904f255ce30","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>把这个新闻移除吧，这关键字抓取的<span>[捂脸]&nbsp;</span>&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>把这个新闻移除吧，这关键字抓取的<span>[捂脸]&nbsp;</span>&nbsp;</p></body></html>","text":"把这个新闻移除吧，这关键字抓取的[捂脸]","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/420518995935528","repostId":2524997472,"repostType":2,"repost":{"id":"2524997472","kind":"news","pubTimestamp":1743644922,"share":"https://www.laohu8.com/m/news/2524997472?lang=zh_CN&edition=full","pubTime":"2025-04-03 09:48","market":"us","language":"zh","title":"亿胜生物科技高开逾4% HLX04-O三期临床研究结果已达到主要研究终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2524997472","media":"新浪网","summary":"亿胜生物科技早盘高开逾4%，截至发稿，股价上涨2.41%，现报4.68港元，成交额789.34万港元。4月2日，亿胜生物科技发布公告，用以治疗湿性AMD中国患者的anti-VEGF眼用注射生物药品的三期临床研究结果已达到主要研究终点。据介绍，HLX04-O是在复宏汉霖自主研发的汉贝泰?除已达到主要研究终点的AURA-1外，HLX04-O在湿性AMD患者中开展的国际多中心三期临床研究正于多个欧洲国家、澳大利亚、美国及中国有序开展，并于2025年一月完成最后一名患者的最后一次访视。","content":"<html><body><article><img src=\"https://fid-75186.picgzc.qpic.cn/20250403103448280v201ka8o8i5wk66\"/><p><a href=\"https://laohu8.com/S/01061\">亿胜生物科技</a>早盘高开逾4%，截至发稿，股价上涨2.41%，现报4.68港元，成交额789.34万港元。</p><p>4月2日，亿胜生物科技发布公告，用以治疗湿性AMD中国患者的anti-VEGF眼用注射生物药品（HLX04-O）的三期临床研究（AURA-1）结果已达到主要研究终点。</p><p>据介绍，HLX04-O是在<a href=\"https://laohu8.com/S/02696\">复宏汉霖</a>自主研发的汉贝泰? （贝伐珠单抗注射液）的基础上，根据眼科用药的需求对汉贝泰? （贝伐珠单抗注射液）的处方、规格和生产工艺进行优化，在活性成分不变的基础上，开发的新的眼科制剂产品，拟用于湿性AMD的治疗。</p><p>除已达到主要研究终点的AURA-1外，HLX04-O在湿性AMD患者中开展的国际多中心三期临床研究正于多个欧洲国家、澳大利亚、美国及中国有序开展（AURA-2），并于2025年一月完成最后一名患者的最后一次访视。</p><p>【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱：news_center@staff.hexun.com</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>亿胜生物科技高开逾4% HLX04-O三期临床研究结果已达到主要研究终点</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n亿胜生物科技高开逾4% HLX04-O三期临床研究结果已达到主要研究终点\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-03 09:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040310345194ca8f2a&s=b><strong>新浪网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>亿胜生物科技早盘高开逾4%，截至发稿，股价上涨2.41%，现报4.68港元，成交额789.34万港元。4月2日，亿胜生物科技发布公告，用以治疗湿性AMD中国患者的anti-VEGF眼用注射生物药品（HLX04-O）的三期临床研究（AURA-1）结果已达到主要研究终点。据介绍，HLX04-O是在复宏汉霖自主研发的汉贝泰? （贝伐珠单抗注射液）的基础上，根据眼科用药的需求对汉贝泰? （贝伐珠单抗注射液...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040310345194ca8f2a&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","LU2360106780.USD":"BGF WORLD TECHNOLOGY \"A4\" (USD) INC","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","BK4573":"虚拟现实","LU0642271901.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD-H","IE00B5949003.HKD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A\" (HKD) ACC","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","LU1803068979.SGD":"FTIF - Franklin Technology A (acc) SGD-H1","BK4554":"元宇宙及AR概念","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","BK4543":"AI","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","LU0081259029.USD":"UBS (LUX) EQUITY FUND - TECH OPPORTUNITY \"P\" (USD) ACC","BK4141":"半导体产品","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU1316542783.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD","LU0823421416.USD":"BNP PARIBAS DISRUPTIVE TECHNOLOGY \"C\" (USD) INC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0823421333.USD":"BNP PARIBAS DISRUPTIVE TECHNOLOGY \"C\" (USD) ACC","AMD":"美国超微公司","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","BK4566":"资本集团","BK4575":"芯片概念","LU0889565833.HKD":"FRANKLIN TECHNOLOGY \"A\" (HKD) ACC","LU0056508442.USD":"贝莱德世界科技基金A2","LU2054465674.USD":"UBS (LUX) KEY SELEC SICAV DIGITAL TRANSFORMATION T \"P\" (USD) ACC","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","BK4612":"AI芯片","LU2098885051.SGD":"JPMorgan Funds - Multi-Manager Alternatives A (acc) SGD","GFS":"GLOBALFOUNDRIES Inc.","BK4614":"Manus概念股","LU1852331112.SGD":"Blackrock World Technology Fund A2 SGD-H","LU2458330169.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A\" (SGD) ACC","LU1880398471.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) ACC","BK4588":"碎股","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU1880398554.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) INC","BK4605":"半导体精选","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU2458330243.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A-H1\" (SGDHDG) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","LU0109392836.USD":"富兰克林科技股A","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040310345194ca8f2a&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2524997472","content_text":"亿胜生物科技早盘高开逾4%，截至发稿，股价上涨2.41%，现报4.68港元，成交额789.34万港元。4月2日，亿胜生物科技发布公告，用以治疗湿性AMD中国患者的anti-VEGF眼用注射生物药品（HLX04-O）的三期临床研究（AURA-1）结果已达到主要研究终点。据介绍，HLX04-O是在复宏汉霖自主研发的汉贝泰? （贝伐珠单抗注射液）的基础上，根据眼科用药的需求对汉贝泰? （贝伐珠单抗注射液）的处方、规格和生产工艺进行优化，在活性成分不变的基础上，开发的新的眼科制剂产品，拟用于湿性AMD的治疗。除已达到主要研究终点的AURA-1外，HLX04-O在湿性AMD患者中开展的国际多中心三期临床研究正于多个欧洲国家、澳大利亚、美国及中国有序开展（AURA-2），并于2025年一月完成最后一名患者的最后一次访视。【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱：news_center@staff.hexun.com","news_type":1,"symbols_score_info":{"AMD":0.9,"GFS":0.9}},"isVote":1,"tweetType":1,"viewCount":561,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":37,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/420518995935528"}